

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

FULL/LONG TITLE OF THE STUDY

A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF

SHORT STUDY TITLE / ACRONYM: CARDS-CF

RESEARCH REFERENCE NUMBERS

IRAS Number: 304643

SPONSORS Number:21CS025

FUNDERS Number:

PDGNIHR202952

PROTOCOL VERSION NUMBER AND DATE: 3.0 16-Mar-2022

- **This protocol has been designed to ensure regard for the HRA guidance**

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

SIGNATURE PAGE

The undersigned confirm that the following protocol has been agreed and accepted and that the Chief Investigator agrees to conduct the study in compliance with the approved protocol and will adhere to the principles outlined in the Declaration of Helsinki, the Sponsor’s SOPs, and other regulatory requirement.

I agree to ensure that the confidential information contained in this document will not be used for any other purpose other than the evaluation or conduct of the investigation without the prior written consent of the Sponsor

I also confirm that I will make the findings of the study publicly available through publication or other dissemination tools without any unnecessary delay and that an honest accurate and transparent account of the study will be given; and that any discrepancies from the study as planned in this protocol will be explained.

For and on behalf of the Study Sponsor:

Signature:

.....

Date:

...../...../.....

Name (please print):

.....

Position:

.....

Chief Investigator:



Date: 21/12/21

Signature:

Name: (please print):

Prof Alan Smyth

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

KEY STUDY CONTACTS

Chief Investigator	<p>Professor Alan Smyth Professor of Child Health, University of Nottingham Room 1702, E Floor East Block, Queen’s Medical Centre Nottingham University Hospitals NHS Trust Nottingham NG7 2UH Phone: 01158230612 Fax: 01158230626 Email: alan.smyth@nottingham.ac.uk</p>
Sponsor	<p>Nottingham University Hospitals NHS Trust Queen’s Medical Centre, Derby Road, Nottingham, NG7 2UH +44(0)115 9249924 researchsponsor@nuh.nhs.uk</p>
Funder(s)	<p>National Institute for Health Research Programme Development Grant</p>
Key Protocol Contributors	<p>Professor Alan Smyth Professor of Child Health, University of Nottingham Room 1702, E Floor East Block, Queen’s Medical Centre Nottingham University Hospitals NHS Trust Nottingham NG7 2UH Phone: 01158230612 Fax: 01158230626 Email: alan.smyth@nottingham.ac.uk</p> <p>Dr Rebecca Calthorpe Medical Research Fellow, University of Nottingham, E Floor East Block, Queen’s Medical Centre, Nottingham University Hospitals NHS Trust Nottingham NG7 2UH Rebecca.calthorpe@nottingham.ac.uk</p> <p>Professor Kim Thomas Professor of Applied Dermatology Research, University of Nottingham, Room A103 King's Meadow, King's Meadow Campus, Lenton Lane,</p>

	<p>Nottingham NG7 2NR Phone: 0115 846 8632 Email: kim.thomas@nottingham.ac.uk</p>
	<p>Ms Natalie Goodchild PPI representative and user experience Natalie@nataliejohanna.com</p>
	<p>Dr Siobhan Carr Paediatric Respiratory Consultant Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street, Greater London, SW3 6NP S.Carr@rbht.nhs.uk</p>
	<p>Dr Helen Barr Respiratory consultant Nottingham University Hospitals NHS Trust, Nottingham, UK helen.barr@nottingham.ac.uk.</p>
	<p>Professor Daniel Peckham Professor of Respiratory Medicine, University of Leeds, St James University Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, UK, D.G.Peckham@leeds.ac.uk</p>
	<p>Professor Jochen Mainz Paediatric Pulmonologist, Brandenburg Medical School University, Klinikum Westbrandenburg, Germany, j.mainz@klinikum-brandenburg.de</p>
	<p>Professor Alexander Horsley Professor of Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK alexander.horsley@manchester.ac.uk</p>
	<p>Professor Chris Goss</p>

	<p>Professor of Paediatrics, Division of Pulmonary, Critical Care and Sleep Medicine. University of Washington Medical Centre, Health Sciences Building, Seattle, WA, USA cgoss@medicine.washington.edu</p>
	<p>Dr Bu Hayee, Consultant Gastroenterologist, Kings College Hospital NHS Foundation Trust, London, UK b.hayee@nhs.net</p>
	<p>Professor Margaret Rosenfeld Professor of Paediatrics, Seattle Children's Hospital, 4800 Sand Point Way, NE, Seattle, WA 98105 margaret.rosenfeld@seattlechildrens.org</p>
	<p>Dr Iain Stewart Analytical and statistical lead, National Heart and Lung Institute, Imperial College London, Guy Scadding Building, Dovehouse Street, London, UK iain.stewart@nottingham.ac.uk</p>
	<p>Dr Alexander Yule Medical Research Fellow, University of Nottingham, Queen's Medical Centre, Nottingham University Hospitals NHS Trust. Nottingham, NG7 2UH Alex.Yule@nottingham.ac.uk</p>

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

STUDY SUMMARY

Study Title	A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF
Internal ref. no. (or short title)	CARDS-CF
Study Design	<p>CARDS-CF consists of 3 workstreams</p> <p>Workstream 1: A series of focus groups, semi-structured interviews and a survey to develop a patient reported outcome measure (PROM) for daily measurement of gastrointestinal symptom burden in Cystic Fibrosis (CF). This PROM will be trialled daily, for two weeks, on a app.</p> <p>Workstream 2: Study using registry data from the US and UK CF registries to compare trends of pancreatic enzyme use and rates of distal intestinal obstruction syndrome over a 10 year period.</p> <p>Workstream 3: Systematic review of the literature of outcomes and endpoints use in studies investigating interventions to relieve GI symptoms in CF.</p> <p><u>This protocol relates to Workstream 1 only.</u></p>
Study Participants	People with Cystic Fibrosis aged 12 years and over.
Planned Size of Sample (if applicable)	Approximately 20 participants for focus groups and semi-structured interviews, with approximately 100 participants for survey completion and trialling of the PROM in the smartphone app.
Follow up duration (if applicable)	<p>The total time involved will be dependent on the extent of the participant's involvement in the study. PROM development is expected to take 24 months from start date to project completion. Participants may be involved for a maximum of 18 months. A breakdown of their involvement is as follows:</p> <ul style="list-style-type: none"> - Focus group: 1 day - Interview: 1 day - Survey: 1 day - App completion: 2 weeks
Planned Study Period	24 months from project start date to completion.
Research Question/Aim(s)	Through this study, we aim to develop a PROM for GI symptom burden in CF.

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

FUNDING AND SUPPORT IN KIND

FUNDER(S)	DETAILS OF FINANCIAL AND NON FINANCIAL SUPPORT GIVEN
NIHR Programme Development Grant. Reference number: PDG NIHR202952	Funding for using the app provided by uMotif®, data analysis, participant expenses, ancillary costs and dissemination costs.

ROLE OF STUDY SPONSOR AND FUNDER

The sponsor and funder have supported the research after review of the proposed study design. All aspects of the design have been conceived and developed by the investigators. The study sponsor will monitor the study conduct against applicable regulatory standards. The study sponsor and funder will have no role in the conduct, analysis, or interpretation of the study. The sponsor and funders will be consulted for the final decision/s regarding any aspects of this study.

ROLES AND RESPONSIBILITIES OF STUDY MANAGEMENT COMMITTEES/GROUPS & INDIVIDUALS

The Lead Investigator and co-investigators will act as a study steering group. This will entail regular meetings either face to face or conducted online via MS Teams as well as telephone and electronic written communication.

ROLE OF PATIENTS AND THE PUBLIC IN DEVELOPMENT OF THE STUDY

The study has had patient and public involvement throughout its design process. The study is based on a recent James Lind Alliance Priority Setting Partnership for CF.¹ People with Cystic Fibrosis (pwCF), their families and healthcare professionals identified “how can we relieve gastro-intestinal (GI) symptoms, such as stomach pain, bloating and nausea in people with Cystic Fibrosis” as one of the top 10 research priorities in CF. Our work will address this research question. In addition, a co-investigator on this study is a person with CF. She will have ongoing input throughout the study and will sit on the management group for workstreams 1 and 2. She will advise on PROM development, recruitment, and retention of participants. Along with members of a young person’s advisor group, she has advised on content within the participant information sheet and consent development. Finally, focus groups and interviews involving pwCF are essential for completion of this study.

Key Words:

- Cystic Fibrosis
- Gastrointestinal function
- Gastrointestinal symptoms
- Symptom burden
- Patient Reported Outcome Measure

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

LIST of CONTENTS

GENERAL INFORMATION	Page No.
TITLE PAGE	1
SIGNATURE PAGE	2
KEY STUDY CONTACTS STUDY SUMMARY	3
STUDY SUMMARY	6
FUNDING	7
ROLE OF SPONSOR AND FUNDER	7
ROLES & RESPONSIBILITIES OF STUDY STEERING GROUPS AND INDIVIDUALS	7
LIST of CONTENTS	8
STUDY FLOW CHART	9
SECTION	
1. BACKGROUND	10
2. RATIONALE	11
3. RESEARCH QUESTION/AIM(S)	11
4. STUDY DESIGN/METHODS	11
6. STUDY SETTING	17
7. SAMPLE AND RECRUITMENT	19
8. ETHICAL AND REGULATORY COMPLIANCE	21
9. DISSEMINATION POLICY	26
10. REFERENCES	27
11. APPENDICES	29

SHORT TITLE/ACRONYM: CARDS-CF
IRAS: 304643

STUDY FLOW CHART

This project consists of 3 workstreams. The Gantt chart in Figure 1 outlines the proposed timeline for completion of the different workstreams within the project. Workstreams 1 and 2 will run in parallel and are expected to take 2 years from start to completion of the final analysis and write up. This protocol relates to workstream 1 only and the flow chart in Figure 2 displays the expected pathway for this study.




Figure 1: Gantt chart for the proposed timeline for CARDS-CF




Figure 2: Flow diagram for workstream 1, patient reported outcome measure (PROM) development

STUDY PROTOCOL**A Comprehensive Approach To Relief Of Digestive Symptoms In Cystic Fibrosis: CARDS-CF****1. BACKGROUND**

Cystic fibrosis (CF) is an autosomal recessive disorder, caused by mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene encoding for the CFTR protein. CF affects around 10,000 people in the UK with a life expectancy of 49 years in 2019.² Although CF is a multi-system disorder, its impact on the respiratory tract and gastrointestinal (GI) system are of particular clinical importance.³ In the gut, CFTR mutations result in pancreatic exocrine insufficiency in around 85% infants resulting in maldigestion and impaired nutrition,⁴ with adequate nutrition in CF linked to life expectancy.⁵ Due to the success of the newborn screening programme in the UK most people with CF (pwCF) are now identified within the first few weeks of life and commenced on pancreatic enzyme replacement therapy (PERT). Cystic fibrosis has a high associated treatment burden. PERT in particular contributes to this burden, with patients often having to take 25-30 capsules per day.⁶ However, despite this almost all pwCF experience GI symptoms including abdominal pain, flatulence, constipation and bloating.⁷ The associated burden of these GI symptoms can be disruptive to everyday life, with two thirds missing work or school because of this.⁸ This is why “How can we relieve gastro-intestinal symptoms, such as stomach pain, bloating and nausea in people with Cystic Fibrosis?” was identified as one of the top 10 research priorities in a James Lind Alliance Priority Setting Partnership (JLA PSP) in CF conducted by our group.¹

In addition to frequent GI symptoms, other GI manifestations affecting pwCF include distal intestinal obstructive syndrome (DIOS), CF related liver disease (CFRLD) and pancreatitis. DIOS is a severe GI complication in CF defined as a complete intestinal obstruction with an ileo-caecal mass and abdominal distension, thought to result from the accumulation of faecal material at the ileo-caecal valve.⁹ It affected 5.7% pwCF in the UK (2.5% in <16 years and 7.7% in adults)² and 2.1% in the US (<18 years 1.7%, adult 2.4%)¹⁰ in 2019. However, the pathology underlying DIOS and GI symptoms are currently not well understood.

Advances in CF care have seen the development and introduction of CFTR modulator drugs, capable of targeting the basic defect of CF rather than the consequences of CFTR failure. Ivacaftor was first introduced in 2012 suitable for patients with gating mutations. Since then, a number of CFTR modulators have been developed the most recent being the CFTR modulator Ivacaftor/Tezacaftor/Elexacaftor: Kaftrio™ (UK) or Trikafta™ (US). CFTR modulators have already demonstrated dramatic improvements in respiratory outcome measures in CF,¹¹ however the impact of other aspects of the disease, such as within the gut are less well understood.

Although our JLA PSP demonstrated that reducing GI symptoms was a research priority⁸ there is currently a disconnect between this and ongoing clinical trials, with only three ongoing trials investigating GI symptoms in CF.¹² In addition, there is no agreed, validated outcome measures such as biomarkers or patient reported outcome measures in CF for measuring GI symptom burden that can be

used as a primary end point¹³ for trials. The pattern of GI symptoms in CF is similar to functional GI disorders such as irritable bowel syndrome where regulatory guidance requires a daily assessment of symptoms, for efficacy assessment.¹⁴ Therefore, the development of a specific PROM is essential and should include a daily assessment of symptoms.

2. RATIONALE

There are currently no agreed core outcome sets for trials in CF investigating the relief of GI symptoms, or no agreed, validated, patient reported outcome measures (PROM) for GI symptom burden in CF. The rationale for the proposed study is to create a framework that can be used for clinical trials investigating GI symptoms in CF. This study will comprise of PROM development (workstream 1), a registry study (workstream 2) and a systematic review (workstream 3). This protocol relates to workstream 1 only. Work will only begin once favourable ethical approval has been granted and the protocol has been uploaded onto a clinical trial database.

Workstream 2's protocol and ethics application has been developed separately and gained ethical approval by the University of Nottingham's ethics committee. Workstream 3 does not require ethical approval and a detailed protocol including search strategies will be developed separately and registered with PROSPERO database prior to commencing work on this workstream.

3. AIM: WORKSTREAM 1

3.1. Aim: To develop a patient reported outcome measure for daily measurement of gastrointestinal symptoms that can be recorded using a smartphone application (app).

3.2 Objectives

- To develop and refine a conceptual framework of the factors contributing to GI symptom burden.
- To generate a primary list of item questions, to address the conceptual framework.
- To refine the relevance, comprehensiveness, and understandability of the items in the primary list through think aloud interviews and a patient survey.
- To pilot the resulting items for the PROM over a two week period to explore the patient responses when using the PROM to assess content validity.

3.3 STUDY DESIGN AND METHODS OF DATA COLLECTION AND DATA ANALYSIS

3.4.1 STUDY DESIGN

An overview of the study design is outlined in Figure 3 below. We will follow best practice guidance from COSMIN (Consensus-based Standards for the selection of health Measurement Instruments),¹⁵

the US Food and Drug Administration; and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

The study will flow from 1) an initial conceptual framework 2) primary item generation 3) item refinement 4) item selection 5) pilot testing of the PROM. Each stage informs the subsequent stage (Figure 3).




Figure 3. Flow diagram for patient reported outcome measure (PROM) development

1). Initial conceptual framework:

The first stage will be to create a conceptual framework. This will be synthesised from findings from various sources including the results of published work in the field, including an international qualitative study exploring GI symptoms and associated burden in CF.⁸ This included responses from pwCF, their families and healthcare professionals. The conceptual framework will be developed by an expert panel comprising of members of the research team including health professionals caring for pwCF, those with experience in PROM development and a person with CF with experience in marketing and user experience design, in addition to an equal number of pwCF. These members of the panel are considered as co-authors involved in the design of the study, rather than participants.

The construct of interest will focus on the burden of the GI symptoms for pwCF. The intended purpose of the instrument being developed is outlined below;

Intended purpose	Description
------------------	-------------

Intended construct of interest	A pwCF experience of their gastrointestinal (GI) symptom burden. The severity of GI symptoms and the extent to which these GI symptoms negatively impact, disrupt or add significant burden to the life of a pwCF. This will be measured on a daily basis.
Intended target population	PwCF aged 12 and over who are independently, or with minimal assistance, able to answer questions of the burden of their GI symptoms. PwCF younger than 12 may require more support from a parent/ guardian in answering the questions. A parent’s perception of bowel symptoms and burden may be different to that experienced by the child therefore it is not intended for use in those <12 years. It is intended for use for any sex or ethnicity.
Intended context of use	Primarily designed for use in clinical trials for pwCF to assess any type of intervention on GI symptom burden. A secondary aim is that longer term it may be appropriate for use in the clinical setting – either at home or within the healthcare setting.

We will use a formative model to capture all aspects of a patient’s GI symptoms which add to their GI symptom burden. These discussions will be conducted via a variety of methods including a series of teleconferencing and videoconferencing discussions and via email until a consensus on the conceptual framework is reached. Following generation of the initial conceptual framework, a focus group will be conducted over MS Teams consisting of members of the expert panel, adults with CF and young pwCF accompanied by their parents. PwCF involved as part of the focus group will be different to those involved in the expert panel. This focus group is essential to ensure that no key concepts have been omitted from the initial framework. The meetings will be recorded using an audio digital recorder or the MS Teams function and also transcribed. Conducting the meeting in this way will allow for social distancing measures required for pwCF. Our group have experience of engaging with research participants in this way previously.¹⁶ Recruitment of patients is detailed separately in section 4.5. The findings on the focus group will be discussed amongst the expert panel and any changes made to the construct finalised. This will then be used for item generation (stage 2). All transcription of audio and video recordings throughout the study will be performed by either the medical research fellow directly or by using the MS Teams transcription function and checked for accuracy by the medical research fellow.

2). Primary item generation: The expert panel involved in the development of the conceptual framework will generate a primary list of items relating to each of the concepts in the framework. Ideas for items for possible inclusion in the instrument will be submitted by members of the panel ahead of meeting and then discussed as a group. The items will be reviewed for the relevance, ease of understanding and coverage of the concepts contributing to the GI symptom burden construct. They

will be discussed and either kept for inclusion, discarded, or modified before they are used. Final decision on the items will be made by the research team, with decisions informed by pwCF and their families. Through this, a comprehensive list of key items for inclusion in the PROM will be generated. These discussions will be conducted via online methods as outlined above.

3). Item refinement: The items generated through this discussion will then be refined through a series of patient interviews. The interviews will be conducted by the medical research fellow with support from Professor Kim Thomas (co-investigator with experience in qualitative research). The structure of the interviews will be open-ended, semi-structured, “think aloud” interviews with probing techniques to assess the appropriateness of the items for inclusion. The aim of the interviews is to assess the items and consider their relevance, understandability and comprehensiveness to the target audience to ensure construct validity. Construct validity is the degree in which the content of the instrument being developed adequately reflects the initial construct of interest described in stage 1. The interviews will be conducted over the telephone or via phone or video call. These will be recorded either using the record function on Microsoft Teams or using a digital audio recorder, transcribed as described above, and stored securely as described in Section 6.7.

Data will be coded to identify themes within the interviews. NVivo¹⁷ (qualitative data analysis software) may be used to help organise the data. Coding will be conducted by the research fellow with secondary coding on selected transcripts by an independent researcher within the research team. This will allow for any discrepancies in coding to be identified and discussed. We plan to conduct approximately 10 interviews; however, interviews will be continued until no further issues are identified with the items included within the PROM. Interviews will take place in “rounds” so that coding can be iterative and captures any new concepts or issues which may evolve from the data. Any instructions or items which cause confusion or are misinterpreted by pwCF during the interviews will be recorded and amended and then tested in subsequent interviews. Interviews will take place in rounds before and after survey completion (section 4, Item selection) depending on participant feedback and will continue until no new issues emerge. As the instrument is intended for use by people 12 years and over, both young people and adults with CF will be interviewed. Participants will be recruited as per section 3.6. From this, possible items for the PROM will be agreed by the expert team ready for testing within the survey (stage 4, item selection).

4). Item selection: The finalised extended item list of PROM questions created in step 3 will then be tested in a survey using a larger sample size (n= approximately 100). Participants will be recruited as described in section 3.6. For each item included on the list, participants will be asked;

1) Whether the item has increased the burden of their GI symptoms in the last 2 weeks (yes/no question)

2) how disruptive has the item been in the last 2 weeks? This will be rated using an 5 point interval scale (0 (none) to 4 (severely disruptive)).

In addition, participants will also be asked to score for each item the peak severity on the day of the survey ((0 (none) to 4 (severely disruptive)) alongside the anchor question “How would you rate how disruptive your GI symptoms have been in the last 24 hours?” (5 point interval score, 0 (none) to 4 (severe)).

The survey will be made available online via a web-based survey generating platform e.g. SurveyMonkey. Basic demographics of the participants such as CF centre, gender, genotype, whether they have had a transplant and medications used including CFTR modulator status will also be collected. By the end of stage 4, a final item list for the PROM will be generated to be pilot tested as described in stage 5.

Survey analysis

- The percentage of missing data for each item will be assessed. If some items appear to be particularly problematic, for example, 15% of participants don't answer this question, we will consider why this may be and if this item should still be included in any further analyses.
- The distribution of the scores for each individual item will be assessed to determine if all response options are being used by the participants.
- The items will be assessed for frequency of reporting and its associated impact. Frequency will be calculated by the % of participants who had experienced the item (yes/no question) and the burden of this item, by the mean score given for level of disruptiveness (0-4).
- Impact will be calculated by the “frequency” x “burden”
- We will use multivariable linear regressions for each item against the anchor question to ensure the most impactful items are included within the final PROM. The lowest scoring items will be excluded. Analysis will be completed by the medical research fellow supported by the research team and team statistician using PRISM or STATA (statistical data analysis software).
- Further Item refinement (stage 3) may be conducted if needed following the survey to address any questions which may have caused confusion (for example, if a question was commonly omitted to check for understanding).

5). Pilot testing of the PROM: Following final item selection for the PROM, these will be piloted over a 2-week period using a smartphone app. The items will be hosted on an app provided by uMotif® - a medium sized UK company specialising in data recording for clinical trials. The platform is compliant with Good Clinical Practice and Title 21 Code of Federal Regulation part 11. This will ensure that we capture adequate data for later registration of any PROM with the US Food and Drug administration and similar regulators.

Approximately 100 participants will be recruited to complete the PROM on the app. These will be recruited through a variety of means including those who took part in the initial focus groups, interviews and survey, through participating CF clinics and social media. Recruitment is described in section 3.6. Participants will be asked to complete the app daily and record data over a 2-week period which can be viewed by researchers through a research portal presented through the uMotif app. We will collect feedback on the PROM such as engagement and participant attrition rate through this research portal feedback facility. This information may also be used during the study period to contact the participants if engagement drops to encourage engagement and to give the opportunity for participants to raise any issues they may be having with the app. Participants will also be asked to give feedback on their experiences of using the PROM on days 7 and 14 to ascertain its usability. This will help evaluate the participant experience and feasibility of completing the PROM daily using this platform.

The scores from the final PROM will be provided by the uMotif app. Descriptive analysis and non-parametric tests will be used to assess the PROM scores. As part of this, the distribution of the individual item scores chosen as part of the PROM will be assessed and we will consider if floor or ceiling effects have occurred (defined as >15% of participants achieving highest or lowest possible score). If this occurs this may be improved by including more items within future versions of the PROM that will help distinguish between individuals more.

Participants will also complete the CFAbd-score at the beginning and end of the two weeks which will be made available electronically on the app. This is a validated 28-point questionnaire which captures CF GI symptoms over the preceding fortnight, as opposed to the daily burden caused by the GI symptoms proposed for this PROM development. We will use descriptive analysis and non-parametric tests to compare the results with the CFAbd-score. This will also give an indication of the construct validity of our prototype PROM and may also allow us to assess whether any correlation between the CFAbd-score and our PROM is seen.

3.4.2 ENDPOINTS

PRIMARY ENDPOINTS

- Development of a conceptual framework for GI symptom burden in CF
- Use this conceptual framework to develop a patient reported outcome measure in CF for GI symptom burden

CONFIDENTIAL

Page 16 of 30

SECONDARY END POINTS

- Feasibility of daily data capture of the PROM through a smartphone app
- Usability of the PROM on the smartphone app
- Participant attrition rate

3.4.3 STUDY SETTING

Research activities will primarily take place either online or over the telephone as described in detail in section 3.4.1 above. Focus groups will be completed online via MS Teams, and interviews will be conducted via MS Teams, with the option for a telephone call also given to participants. This is important for pwCF who are advised to never meet face to face due to the risk of cross infection of particular bacteria resulting in potentially serious respiratory infections. It also will help to mitigate against any risks posed from social distancing guidance or restrictions in relation to Covid-19. Our group has experience of conducting research in this way.¹⁶ Researchers involved in the focus groups and interviews will conduct these within their home in a private setting, or within the School of Medicine at the University of Nottingham depending on Covid-19 working from home guidance. If MS Teams is unable to be used for any reason, Cisco WebEx will be used, a secure platform for video conferencing supported by the sponsor, Nottingham University Hospitals NHS Trust.

Study recruitment will take place at Nottingham University Hospitals NHS Trust which has two main campuses. These are Queen's Medical Centre (QMC) and City Hospital, Nottingham (CHN) which have paediatric and adult CF centres. This recruitment will be supported by 4 Participant Identification Centres at Leeds Teaching Hospital NHS Trust (Leeds Adult CF Centre), Manchester University NHS Foundation trust (Manchester Adult CF Centre), the Royal Brompton and Harefield NHS Foundation Trust (Royal Brompton Paediatric CF Centre) and Kings College Hospital NHS Foundation Trust (Adult CF Centre). Each site will be able to identify participants based on the inclusion criteria. Patients will also be recruited via social media.

3.5 SAMPLE AND RECRUITMENT

ELIGIBILITY CRITERIA

3.5.1. Inclusion criteria

- Age 12 years or older
- Confirmed diagnosis of CF based on genotype or sweat chloride testing
- Capacity to consent, or to understand the requirements of the study where parental consent is required

3.5.1 Exclusion criteria

- < 12 years age
- Unable to give informed consent

CONFIDENTIAL

Page 17 of 30

3.6 SAMPLING AND RECRUITMENT

Stage 1+2: We will recruit a representative sample of participants for the focus group and interviews through one of the six tertiary CF clinics involved in this study. The six tertiary care cystic fibrosis centres included are listed in section 3.4.3. Potential participants will be identified by their usual care team who will discuss the focus groups and interviews with the patients and provide a Patient Information Sheet (PIS) containing the study teams contact details. Potential participants can either opt in by directly contacting the study team themselves after taking time to consider the information on the PIS, or they can give their consent for the clinical team to pass their contact details to the study team via a secure email for the study team to contact the potential participant. A member of the research team will contact the potential participant, discuss the study, and seek to gain consent as described in section 3.6.2. We plan for 1 focus group, and approximately 10 interviews, although this will continue until no new issues are identified.

Stage 4: Participants will be identified by their usual CF care team whilst in clinic as described above, as well as via social media. They will be given a QR code taking them to the PIS and survey. Consent is detailed in section 3.6.2 below. As part of the participant information and consent, participants will be made aware they will be given the option to leave their contact details if they would like to hear more about future research and to advertise recruitment for Stage 5. We aim to recruit approximately 100 participants to complete the survey.

Stage 5: Participants will be identified by their usual CF care team whilst in clinic as described above, as well as via social media. QR codes will be made available to the app for potential participants taking them to the app store to download the uMotif app, available for iPhone or Android. Participants will be provided with an invite code and asked to sign up using an email address and setting a password. The app will contain a page displaying an overview of the PIS, a link to a detailed PIS and electronic consent. Patients will be asked to read the PIS and give e-consent before giving basic demographics about themselves.

We aim to recruit 100 participants for the pilot testing phase of the PROM on the app. Those completing the app may, but do not have to have taken part in previous stages of PROM development. We will undertake purposive recruitment to aim that we have;

- Approximately 20% of the sample aged 20 years or younger
- Some participants who have had a transplant
- Approximately 10% of participants are not taking CFTR modulators (which may include, but is not restricted to transplanted patients).

To achieve this, participants will be asked to enter baseline characteristics the first time they use the app, such as age, gender, genotype, CF centre, transplant and CFTR modulator status and the use of pancreatic enzymes. The Chief Investigator or a nominee, i.e. the medical research fellow is responsible for ensuring recruitment fulfils these criteria through regular reviews of the enrolment of participants and liaising across the CF centres. Recruitment will be primarily based with the UK, but we will not exclude international participants providing they are able to read the PIS, consent process and PROM questions which will be written in English.

Separate participant information sheets (PIS) have been generated for stage 1 (focus group), stage 2 (interviews), stage 4 (survey) and stage 5 (app use). For the focus group and interviews PIS, 3 types have been generated; a 12-15 years, 16 years+ and a parent/carer PIS. The PIS will inform the potential participant or their representative (such as a parent in the case of children with CF) of all aspects relating to participating in that aspect of the study. It will be explained that entry into the study is entirely voluntary and that their treatment and care will not be affected by their decision. For piloting testing the PROM on the app, this PIS this will also be displayed electronically. As it will not be possible to determine whether a young person or adult has downloaded the app, this information sheet will be written to be accessible to a reading age of 12 years therefore should be appropriate for all participants. Stage 4 PIS is described in section 3.6.2. Although it is also possible that recruitment via social media may allow the potential for people outside our targeted population (i.e. people who do not have CF or less than 12 years) to fill in the survey or use the app, by asking for basic demographic information such as their age, CF centre, and CFTR modulator status, we feel that this is unlikely.

Participants will be made aware that in the event of their withdrawal from the study their data collected so far cannot be erased and we will seek consent to use the data in the final analyses where appropriate. Only English-speaking participants will be enrolled into the study due to the lack of availability of funding to conduct the interviews via interpreters and that also the pilot app will be developed in English. Further work to develop translations into other languages and cross-cultural validation studies will be required at a later stage once an English version of the PROM has been developed. We will aim to include people within our expert panel that speak common languages to help highlight any words which may not be easily translated.

Participants involved in the focus group and interviews will be compensated for their time with a £30 shopping voucher made available in the appropriate format for the patient as a mark of thanks. The first 100 people to complete the pilot testing of the PROM in the app will receive a £10 electronic shopping voucher in the appropriate format to their registered email address. No reimbursements will be given for participants involved in completion of the survey as participants can complete it at a time and place suitable for them and will likely have minimal impact on the individual's time.

3.6.2 CONSENT

Stage 1+2

All participants involved in the focus groups and interviews will be identified by their clinical care team who will provide information to the potential participants and the PIS with the study team's contact details on. Participants can either take the information away to read at a time convenient to them before contacting the study team themselves therefore having time to consider whether to participate or not. They can also give consent for the clinical team to pass on their information to the study team who will make contact, check eligibility criteria, gain electronic consent for the study and arrange a date for the focus group or interview. Participants will be made aware as part of the consent that these will be recorded. Consent will be completed electronically following HRA/MHRA guidance on seeking

consent by electronic methods.¹⁸ Informed consent will be taken prior to conducting the interview. In the case of a young person with CF, an e-consent from a person with parental responsibility is required, but the child may also provide assent (optional, depending on the young person's ability to do so). A parent/ guardian will be responsible for their child's safety to monitor their child to ensure they are safe when online. The medial research fellow anticipated to conduct these interviews has an up to date DBS check.

Stage 4

We will recruit adults and young people 12 years and over with CF. Participants who are interested in completing the survey will use a QR code to the survey where they will first be provided with more information for the study. They will be asked to read the information, which will include eligibility criteria, research aims, voluntary nature of taking part, what will happen to the data they provide and withdrawal procedures. There will be an option to select to confirm that they have read the information and are happy to proceed. It will be made clear to them that by ticking the box or completing any part of the survey that they are providing their consent to take part in the survey. For young people under the age of 16 they will be asked to confirm they have discussed the information with their parent/ guardian and they have given their permission to take part in the survey. Although it is possible a child will participate without the informed consent of a parent/ guardian monitoring this will be beyond the control of the researchers.

Stage 5

The participant information sheet as described in section 3.6.1 will be displayed on the app front page detailing the study aim, eligibility criteria, aims, what participants are required to do as part of piloting testing the PROM on the app, and how their data will be used. There will also be a link available to a full PIS. The research study team's contact details will be made available if participants require any further information and will also be able to request a call back from the study team. Participants will be asked to read a series of statements to show that that have read and understood the information and complete a simple electronic consent prior to using the app. If a young person takes part in the use of the app, they will require a parent/ guardian to provide consent for them. It is the parents' responsibility to monitor their child to ensure their child is safe online.

Should there be any subsequent amendment to the final protocol, which might affect a participant's participation, continuing consent will be obtained using an amended consent form which will be signed by the participant.

3.6.3 WITHDRAWAL

Participants may be withdrawn from any aspect of the study at their own request or at the discretion of the Investigator. The participants will be made aware that this will not affect their future care.

Participants will be made aware (via the information sheet and consent form) that should they withdraw the data collected to date cannot be erased and may still be used in the final analysis.

ETHICAL AND REGULATORY CONSIDERATIONS

4.1 ASSESSMENT AND MANAGEMENT OF RISK

There is a low level of risk or burden for participants in the study. No investigational medicinal product will be used, and participants will not be asked to alter or abstain from any of their medications related to their CF or GI symptoms. App completion over a 2-week period is not anticipated to add significantly to treatment burden.

A possible risk identified is the identification of patients through the focus group, interview, survey or app suggestive of needing medical attention, for example exacerbation of symptoms or symptoms indicating potential DIOS. It will be made clear to participants at study entry that data collected via the survey and app will not be reviewed regularly by clinicians and their results are for research purposes only. They will be advised on study entry that any worsening symptoms should prompt them to seek advice from their usual healthcare professional. A reminder of this will also appear within the app. For the patient interviews where participants will have direct contact with the research team, no advice on symptom management will be given. However, if through discussion worsening clinical symptoms are noted they will be advised to speak to the relevant healthcare professional from their usual CF team. These participants will also be discussed with the Chief Investigator who will pass information if appropriate to their usual CF centre with the patient's consent. Similarly, if during participation of the interviews or app it raises any feelings of distress to participants, they will be directed to their CF Team and relevant support services which will be provided by the research team at the end of the focus groups, interviews, or within the app.

5.1 RESEARCH ETHICS COMMITTEE (REC) REVIEW AND REPORTS

This study will not start before ethical approval has been gained from the National Research Ethics Service, through the Health Research Authority. The review by National Research Ethics Service will include a review by a Research Ethics Committee (REC). The REC will include review of the protocol, participant information sheets and consent form.

Substantial amendments that require review by REC will not be implemented until the REC grants a favourable opinion for the study. All correspondence with the REC will be retained.

It is the Chief Investigator's responsibility to produce the annual reports as required. The Chief Investigator will notify the REC of the end of the study. An annual progress report (APR) will be submitted to the REC within 30 days of the anniversary date on which the favourable opinion was given, and annually until the study is declared ended.

If the study is ended prematurely, the Chief Investigator will notify the REC, including the reasons for the premature termination. Within one year after the end of the study, the Chief Investigator will submit a final report with the results, including any publications/abstracts, to the REC.

6.1 PEER REVIEW

The study design has been formulated through collaboration of co-applicants at the six involved CF centres as well as with co-applicants within the US and Germany who are experts within the field of Cystic Fibrosis. Independent internal peer review was completed through the School of Medicine as part of the funding application and submission process for external grant applications. NIHR peer review was also undertaken prior to awarding funding as part of the programme development grant.

6.2 PATIENT AND PUBLIC INVOLVEMENT

This study is in response to a James Lind Alliance Priority Setting Partnership for CF.¹ “How can we relieve gastrointestinal symptoms, such as stomach pain, bloating and nausea in people with Cystic Fibrosis” was ranked the 2nd most important research priority amongst pwCF, their families and healthcare professionals. CARDS-CF has had patient and public involvement throughout its design process. A co-applicant central in the development of this study is a person with CF. She will have continued involvement and will sit on the management group for workstreams 1 and 2. She will advise on PROM development, recruitment, and retention of participants. Along with members of a Young Person’s Advisory Group, she has contributed to the content of the PIS and consent. The development of the PROM through focus group, interviews, surveys and trialling its use within the app is only possible through engagement with pwCF and their families. Our initial priority setting partnership work developed social media tags that can be used to disseminate the results through patient networks.

6.3 REGULATORY COMPLIANCE

Before any site can inform patients about the study, the Chief Investigator/Principal Investigator or designee will apply for Health Research Authority (HRA) approval for the study and will contact all potential site R&D department and, if applicable, the local Clinical Research Network. Prior to commencing recruitment, sites must confirm their capacity and capability to conduct the study, as per the HRA approval letter.

Any amendment to the protocol should be considered that it may potentially affect a site’s capacity to continue in the study, the Chief Investigator or designee will inform the Sponsor of the proposed amendment. The amendment will be submitted as per Section 6.7.

6.4 PROTOCOL COMPLIANCE

Accidental protocol deviations can happen at any time. If this occurs, they must be adequately documented on the relevant forms and reported to the Chief Investigator and Sponsor immediately.

Deviations from the protocol which are found to frequently recur are not acceptable, will require immediate action and could potentially be classified as a serious breach.

6.5 AMENDMENTS

Proposed amendments will be presented to the Sponsor prior to their enactment. It is the sponsor's responsibility to decide whether an amendment is substantial or non-substantial for the purposes of submission to the REC. If the sponsor wishes to make a substantial amendment to the REC application or the supporting documents, the sponsor must submit a valid notice of amendment to the REC for consideration. Site R&D departments will also need to be provided with the information on the amendment in order to assess their continued capacity and capability.

Non-substantial amendments also need to be notified to the REC as well as the relevant R&D departments of participating sites to assess whether the amendment affects the continued capacity for that site.

The amendment history will be numerically tracked to identify the most recent protocol version.

6.6 ADVERSE EVENTS

Reporting Procedures: Proportionate to the type of study and participant involvement, all adverse events will be reported. Depending on the nature of the event the reporting procedures below should be followed. Any questions concerning adverse event reporting will be directed to the Chief Investigator in the first instance.

Definitions

Adverse Event (AE): any untoward medical occurrence in a patient or clinical study subject.

Serious Adverse Event (SAE): any untoward and unexpected medical occurrence or effect that:

- Results in death
- Is life-threatening – refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe
- Requires hospitalisation, or prolongation of existing inpatients' hospitalisation
- Results in persistent or significant disability or incapacity
- Is a congenital anomaly or birth defect

Medical judgement should be exercised in deciding whether an AE is serious. Important AEs that are not immediately life-threatening or do not result in death or hospitalisation but may jeopardise the subject or

SHORT TITLE/ACRONYM: CARDS-CF
 IRAS: 304643

may require intervention to prevent one of the other outcomes listed in the definition above, should also be considered serious.

Non serious AEs: All such events, whether expected or not, should be recorded.

Serious AEs: An SAE form should be completed and sent to the Chief Investigator within 24 hours. However, relapse and death due to Cystic Fibrosis and hospitalisations for elective treatment of a pre-existing condition do not need reporting as SAEs.

All SAEs should be reported by the Chief Investigator directly to REC where in the opinion of the Chief Investigator, the event was:

‘related’, ie resulted from the administration of any of the research procedures; and

‘unexpected’, ie an event that is not listed in the protocol as an expected occurrence

In this instance, RDSAE@nuh.nhs.uk should be copied into all correspondence with the REC. Reports of related and unexpected SAEs should be submitted within 15 days of the Chief Investigator becoming aware of the event, using the TAFR01910 SAE form for non-IMP studies. Local investigators should report any SAEs as required by their Local Research Ethics Committee and/or Research & Development Office.

Sponsor Contact Details for SAEs:

- I. Email (RDSAE@nuh.nhs.uk)
- II. Hand delivered not mailed (R&I, NHSP, C Floor, South Block, QMC)

Any queries please contact a member of staff in the Research & Innovations department:

Email: researchsponsor@nuh.nhs.uk

6.7 DATA PROTECTION AND PATIENT CONFIDENTIALITY

GENERAL PRINCIPLES

All investigators and study site staff will comply with the requirements of the General Data Protection Regulation 2018 and Data Protection Act 2018 with regards to the collection, storage, processing and disclosure of personal information and will uphold the Regulation’s/Act’s core principles. Nottingham University Hospitals NHS Trust will act as Data Controller for the study.

Commercial software packages will be used throughout the project. For all software used, the appropriate usage licences will be held through the University of Nottingham. Statistical analysis will be performed using NVIVO, Stata or PRISM software. Microsoft Teams will be used for the video and audio recording and transcription of the focus group and interviews. Microsoft Teams is an ISO 27001, information-security-management compliant service that allows secure and controlled sharing of data, including video and audio recordings. Microsoft Teams encrypts data both in transit and at rest and is

CONFIDENTIAL

Page 24 of 30

approved against the University's Handling Restricted Data Policy. The service provides continual failover support. Microsoft Teams also allows for data segregation via private channels, meaning that sub-project folders can have strict access controls. In addition, the University of Nottingham licences Microsoft OneDrive, an ISO27001 information security management complaint service for storage of working data. This allows secure and controlled sharing of data amongst relevant members of the research team. Any off site working with the data will be backed up and stored on the University of Nottingham OneDrive as soon as possible. If MS Teams is unable to be used for any reason, Cisco WebEx will be used, a secure platform for video conferencing supported by the sponsor, Nottingham University Hospitals NHS Trust.

Data will be stored in the overall umbrella folder "CARDS-CF" in which a README folder will be created with a file describing the project aim, objectives, statistical analysis plan along with a detailed protocol. A descriptive metadata will also be included within this folder. The metadata will be sufficient to allow others to understand what research data exists and how to access them. Version control will be accounted for by labelling the file as "FILE NAME_DATE_"

For all aspects of the study, to maintain anonymity participants will be pseudonymised and assigned a study ID number (random 3 digit number). This will be used to allow the separation of personal data from the participant responses to maintain confidentiality. Video and audio recordings for the interviews will be labelled with the study ID number only with the files only accessible to researchers at the University of Nottingham. A data file matching the study ID number to the participant's identifiable information will be held in a separate, secure, password-protected University of Nottingham Microsoft OneDrive file. For the focus group, as there will be a number of people participating, participants will still be assigned a study ID number with their details stored in a separate data file as outlined above. The recording will also be labelled with a generic 3 digit code and this code stored in the data file. Participants will be made aware through the participant information sheet and during the focus groups to maintain confidentiality of other members of the focus group and not share their information or the content of the focus group outside the session.

The Chief Investigator will decide on the appropriateness of sharing data related to this study following a formal request for data or collaboration. Microsoft OneDrive and SharePoint allows for secure and controlled sharing of data if a request for data sharing is approved. Following study completion, the Investigator Site File, Sponsor Trial Master File and study documents shall be finally archived by the sponsor at secure archive facilities according to Sponsor SOP's.

STAGE SPECIFIC DATA MANAGEMENT

Stages 1 and 2

All data generated as part of focus groups or interviews will be transcribed verbatim. The audio recording and electronic copies of the data will be stored on Microsoft OneDrive. These will be stored separately in password protected files.

Stage 4

Data will be generated using a secure web-based survey generating platform. Data will be downloaded and stored securely on Microsoft OneDrive. For participants who gave their contact details to be contacted about further work relating to the study, these will be separated from the results and stored as a separate password protected file prior to analysis of the results. This will preserve confidentiality of the participant responses and provide anonymity of the participants.

Stage 5

The sponsor will remain the data controller and uMotif is the Processor. Data processing and the management of the data provided by uMotif via use of the app is outlined in detail as a separate Data Processing document. Only basic participant demographic information will be collected, and any personal identifiable information provided by the participant such as contact details will be separated from the to the participant's responses to maintain confidentiality. A sub-contract is in place between the University of Nottingham and uMotif in which the University of Nottingham is the data controller and owns the Intellectual Property in order for the University of Nottingham to give this in turn to Nottingham University Hospitals NHS Trust who are leading the study.

6.8 INDEMNITY

As Nottingham University Hospitals NHS Trust is acting as sponsor for this study, NHS indemnity applies. NHS bodies are legally liable for the negligent acts and omissions of their employees. Non-negligent harm is not covered by the NHS indemnity scheme. The Nottingham University Hospitals NHS Trust, therefore, cannot agree in advance to pay compensation in these circumstances. In exceptional circumstances an ex-gratia payment may be offered.

6.9 ACCESS TO THE FINAL STUDY DATASET

All investigators at the University of Nottingham will have access to the full dataset. Decision to grant access to study investigators at other sites to the full dataset will be at the discretion of the Chief Investigator.

7 DISSEMINATION POLICY

Access to the data generated will be granted to all named co-investigators at the University of Nottingham. Anonymised data from the study will be made available subject to reasonable request to the Chief Investigator. On completion of the study, the data will be analysed and a Final Study Report prepared and sent to NIHR. Funders will be acknowledged within the publications but do not have any rights for review or approval of data for publication. Participating investigators can only publish any of the study data following approval from the chief investigator. At the end of the study we will also hold an online dissemination event for pwCF in addition to preparing a lay summary of the findings and also disseminating the results via social media accounts.

8. REFERENCES

1. Rowbotham NJ, Smith S, Leighton PA, Rayner OC, Gathercole K, Elliott ZC, et al. **The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.** *Thorax*. 2018. **73**(4):388-90,
2. UK Cystic Fibrosis Trust. UK CF Registry. Annual Data report 2019. . London: Cystic Fibrosis Trust.; 2020.
3. Elborn JS. **Cystic fibrosis.** *Lancet*. 2016. **388**(10059):2519-31,
4. Singh VK, Schwarzenberg SJ. **Pancreatic insufficiency in Cystic Fibrosis.** *J Cyst Fibros*. 2017. **16 Suppl 2**:S70-s8,
5. Corey M, McLaughlin FJ, Williams M, Levison H. **A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto.** *J Clin Epidemiol*. 1988. **41**(6):583-91,
6. Davies G, Rowbotham NJ, Smith S, Elliot ZC, Gathercole K, Rayner O, et al. **Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials.** *J Cyst Fibros*. 2020. **19**(3):499-502,
7. Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, et al. **Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings.** *PLoS One*. 2017. **12**(5):e0174463,
8. Smith S, Rowbotham N, Davies G, Gathercole K, Collins SJ, Elliott Z, et al. **How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey.** *BMJ Open Respiratory Research*. 2020. **7**(1):e000614,
9. Houwen RH, van der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. **Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS.** *J Pediatr Gastroenterol Nutr*. 2010. **50**(1):38-42,
10. Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report2019. Available from: <https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf>.
11. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. **Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.** *N Engl J Med*. 2019. **381**(19):1809-19,
12. Kalaitzis IS, Rowbotham NJ, Smith SJ, Smyth AR. **Do current clinical trials in cystic fibrosis match the priorities of patients and clinicians? A systematic review.** *J Cyst Fibros*. 2020. **19**(1):26-33,
13. European Medicines Agency. Report on Enpr-EMA workshop on gastrointestinal (GI) outcome measures to evaluate CFTR modulators for the treatment of cystic fibrosis (CF).2016. Available from: https://www.ema.europa.eu/en/documents/report/report-european-network-paediatric-research-european-medicines-agency-workshop-gastrointestinal-gi_en.pdf.
14. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Drugs for Treatment2012. Available from: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irritable-bowel-syndrome-clinical-evaluation-products-treatment>.
15. Terwee CP, Cecilia; Chiarotto, Alessandro; de Vet, Henrica; Bouter, Lex; Alonso, jordi; Westerman, Marjan; Patrick, DONald; Mokkink, Lidwine;. COSMIN methodology for assessing the

content validity of PROMs2018. Available from: <https://cosmin.nl/wp-content/uploads/COSMIN-methodology-for-content-validity-user-manual-v1.pdf>.

16. Rowbotham NJ, Smith SJ, Elliott ZC, Leighton PA, Rayner OC, Morley R, et al. **Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis.** *Research Involvement and Engagement*. 2019. 5(1):24,

17. QSR International Pty Ltd. NVivo. 2020.

18. Health Research Authority MaHpRA, . Joint statement on seeking consent by electronic methods2018. Available from: <https://s3.eu-west-2.amazonaws.com/www.hra.nhs.uk/media/documents/hra-mhra-econsent-statement-sept-18.pdf>.

7.1 Appendix 1- Required documentation

- Participant Information Sheets (paper copy and electronic) – Focus Group (12-15 years, parents/carer, 16years+)
- Participant Information Sheets (paper copy and electronic) – Interview (12-15 years, parents/carer, 16years+)
- Participant Information Sheets (electronic) – Survey
- Participant Information Sheets (paper copy and electronic) – App use
- Consent forms – Focus group (parents/carer, 16years+)
- Consent forms – Interview (parents/carer, 16years+)

7.2 Appendix 3 – Amendment History

Amendment No.	Protocol version no.	Date issued	Author(s) of changes	Details of changes made
1	3.0		R.C	Typographical errors, PI for King’s College PIC site updated